Why BGPT?
logo

Science's Data Search Engine

Results grounded in experimental data—not abstracts.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    TFE3 tissue roles table (hepatocyte, muscle, adipocyte, tumor) is below, synthesized from a TFE3 metabolic-regulation review that explicitly covers these cellular contexts and mechanism themes (insulin signaling, glucose/lipid metabolism, lysosomal/autophagy–mitophagy, and cancer-associated programs).



     Long Explanation


    TFE3: tissue-specific roles (hepatocyte, muscle, adipocyte, tumor)
    Evidence source: a TFE3 metabolic-regulation review covering multiple tissue contexts and mechanism themes.
    Evidence grounding & skepticism
    • Known / described: the review explicitly links TFE3 to insulin signaling and glucose/lipid metabolism, plus mitochondrial/autophagy/lysosomal programs in multiple tissues and tumor contexts.
    • Uncertainty: the review notes cross-species/model variability and limitations of overexpression/knockout systems, and that adipose-browning-related conclusions may be context dependent/debated.
    • Reproducibility caveat: synthesized literature—no new primary data are reported in the cited source.
    1) TFE3 tissue-role mapping (table)
    Tissue / context Metabolic program themes linked to TFE3 Mechanistic interactions highlighted Evidence type in the source (as described) Key caveats in the source
    Hepatocyte Insulin signaling alignment; regulation of glucose and lipid metabolism; coupling to mitochondrial/autophagy/lysosomal processes. IRS-2 / FOXO1 / SREBP-1c / PGC-1α axis and broader MiT TF metabolic regulation themes. Synthesized mechanistic evidence; models include mouse liver manipulations and hepatocyte contexts as referenced. Cross-model variability; endogenous vs transgene/KO effects may diverge.
    Muscle (skeletal) Glucose/lipid metabolic control connected to energy-homeostasis programs, with links to mitochondrial/autophagy/lysosomal regulation. Mechanism themes referenced as part of the integrated insulin–metabolism–MiT TF framework. Synthesized tissue-level mechanistic literature across cited models. Context dependence across experimental systems; translational uncertainty.
    Adipocyte Insulin signaling/metabolic regulation with attention to mitochondrial/autophagy–lysosomal coupling; possible role in adipose browning/thermogenic directionality (discussed as debated). Integrated interaction network themes (insulin/FOXO/SREBP/PGC-1α) presented in the review framework. Synthesized evidence including adipose-related mouse models and adipocyte contexts as referenced. Adipose browning conclusions are specifically flagged as conflicting/debated.
    Tumor (e.g., RCC, ASPS) Cancer metabolic reprogramming tied to autophagy/lysosome and mitochondrial dynamics; transcriptional programs driven by TFE3 alterations including fusions. Discussion includes tumor-relevant TFE3 contexts such as Xp11 translocation RCC and alveolar soft part sarcoma, within the TFE3–autophagy/mitochondria metabolic theme. Synthesized cancer mechanistic literature; tumor models and cell line references mentioned in the source description. Model/system differences and variable mechanistic readouts; limited direct clinical data in the review’s framing.
    Table basis: all tissue-role themes in this table are synthesized from the cited review source.
    2) Visual summary: which mechanism themes are emphasized where
    Important limitation: the review provides synthesis, not tissue-by-tissue quantitative coefficients; therefore this plot is qualitative emphasis (0–3) inferred from the described themes, not measured values.
    3) Network diagram: pathway fragments mentioned in the source
    Source-limited scope: only interaction fragments explicitly mentioned in the review excerpt description are shown (IRS-2/FOXO1/SREBP-1c/PGC-1α and REV-ERBα, plus mitochondrial/autophagy–lysosome and glucose/lipid metabolism themes).
    What would falsify or strongly change this tissue-role map?
    • Loss-of-function in a given tissue (e.g., liver or adipose) would not alter insulin sensitivity or glucose/lipid metabolism as claimed by the integrated model.
    • TFE3 manipulation would not shift the proposed regulatory targets (IRS-2/FOXO1/SREBP-1c/PGC-1α-related gene expression changes).
    • For adipose browning/thermogenic claims, in vivo TFE3 activity would not produce the proposed effects under defined conditions—particularly given the review’s stated debate/conflicting findings.
    Single-source limitation: In this response, the tissue mapping is grounded only in the provided review record.


    Feedback:    

    Updated: April 11, 2026

     Hypothesis Graveyard


    A simplistic “TFE3 always increases insulin sensitivity” model is unlikely to hold across tissues because the source flags cross-model/species variability and conflicting adipose outcomes, implying bidirectionality or context dependence.


    A “TFE3’s main role is only mitochondrial dynamics, not lysosome/autophagy” explanation is disfavored by the review’s explicit emphasis on mitochondrial/autophagy and lysosomal biogenesis coupling.

     Science Art


    Create Tables: TFE3 tissue specific roles (hepatocyte, muscle, adipocyte, tumor) Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending